Background: In Hampshire Hospitals NHS Foundation Trust, in addition to an on-the-spot investigation into hospitalonset Clostridium difficile infection (CDI) by the infection prevention team, a multidisciplinary team root cause analysis (MDT-RCA) forum has been developed. The MDT-RCA aims to deliver a more thorough investigation into individual cases and the recommendation of cases to the clinical commissioning groups (CCG) appeals panel against potential financial penalties (£10,000 per breached case). We mainly aimed to investigate the financial impact of MDT-RCAs to the Trust.
Introduction
Between 1990 and 2004, rates of Clostridium difficile infections (CDI) changed in different age groups in England, with the greatest increase occurring in those aged 60-64 years. Changes in healthcare provision, laboratory testing and patient risk factors may have contributed to this. Complex epidemiological changes including the emergence of more virulent strains such as ribotype 027 associated with more severe disease, higher mortality and relapse rates, and outbreaks may have also been a driving factor (Freeman et al., 2010 High CDI rates in the early 2000s led to concerted efforts by the NHS to reduce the incidence of infections, mainly through promoting strict infection prevention practices and antimicrobial stewardship. Mandatory reporting and CDI targets were also introduced for hospitals and Trusts. These efforts have been very successful with the incidence of reported C. difficile in England declining by approximately 80% since 2006 (Dingle et al., 2017) . This was followed by a more complex change in the epidemiological landscape of CDI, including a lack of predominant circulating strains, new laboratory testing and technologies as well as reports suggesting that patient-to-patient transmission in hospital of particular strains of C. difficile is not currently a major feature of reported CDIs (NHS England, 2014) .
Subsequently new guidance was published on the diagnosis and reporting of CDI (Department of Health, 2012) . The guidance recommended the combination of two tests, the first of which should be either a nucleic acid amplification test (NAAT), which detects the presence of toxin gene, or a glutamate dehydrogenase (GDH) test, which detects an antigen that is produced in high amounts by both toxinproducing and non-toxin-producing C. difficile strains. The second test should be a sensitive toxin enzyme immunoassay (EIA) that detects the presence of toxins (Department of Health, 2012) . Additionally, interpretations of test results and mandatory reporting were also changed. Two test-positive results (NAAT + EIA or GDH + EIA) must be included in mandatory reporting regardless of presence of disease. If GDH or the NAAT alone is positive, then although C. difficile could be present, mandatory reporting is not required (Department of Health, 2012) . No test, or combination of tests, is infallible and the clinical condition of the patient should always be taken into consideration when making management and clinical choices.
There is a continuing requirement for NHS organisations to demonstrate year-on-year reductions in C. difficile cases based on the previous year's trend reduction in C. difficile cases. NHS England publishes CDI objectives (targets, ceilings) for acute trusts and clinical commissioning groups (CCG) for each financial year (NHS Improvement, 2017) . Their aim is to drive continuous improvement from healthcare providers. In addition to targets, NHS England also publishes guidance setting out how CCGs can exercise discretion in deciding whether or not to impose sanctions on providers for breach of their C. difficile targets, taking into account specific circumstances relating to individual cases, reasons for a particular infection and determining whether sanctions are appropriate.
Like any incident in the healthcare system, it is recognised that lessons should be learnt following each CDI and that this learning should be shared and acted upon to prevent the same incident occurring to others and elsewhere. Root cause analysis (RCA) investigation is a wellrecognised mechanism within the NHS to identify how and why patient safety incidents happen, to identify areas for improvement and develop recommendations that deliver safer care for patients.
Hampshire Hospitals NHS Foundation Trust (HHFT) has contractual agreements with five local CCGs. The infection prevention team reports all healthcare-acquired infection (HCAI) incidents to the relevant appropriate CCGs via the clinical governance team. Breaches of C. difficile targets incur financial penalties to the Trust to the value of £10,000 per case. The CCGs have decided to offer an appeal process for inpatient HCAI CDIs during which cases are presented to a CCG panel. If the panel members find that no lapse of care occurred, based on rigorous standards set out by the CCGs, then the Trust may avoid financial penalties for those cases. However, these cases remain apportioned to the Trust.
In HHFT, in addition to an on-the-spot RCA by the infection prevention and control nurses (IPCN) in conjunction with the ward staff generating real-time feedback, a new model multidisciplinary team root cause analysis (MDT-RCA) forum was developed in June 2014. The MDT-RCA forum is composed of core members including the Director of Infection Prevention and Control (a microbiologist/infectious disease physician), lead IPCN, surveillance officer, antimicrobial pharmacist, domestic manager, governance manager as well as an administrator and invited members including clinicians, nurses and ward managers for affected patients and areas. The main aim of the MDTRCAs is to deliver a more rigorous investigation that maximises our learning from HCAIs and allows cases to be referred to the CCG panel for appeal against potential financial penalties. The main objectives of this report are to share our findings through a review of data from 24 months of MDT-RCA (June 2014 to June 2016) and to identify the impact of the process on: (1) identifying cases that can be referred to appeal in order to avoid potential financial penalties; and (2) the cost of MDT-RCA to the Trust versus potential savings from the appeal process.
To our knowledge there are no published reports that address these objectives.
Methodology

Location, bed numbers and targets
HHFT serves a population of approximately 600,000 across Hampshire and parts of West Berkshire. The Trust consists mainly of two major district general hospitals (Winchester and Basingstoke) and a community hospital (Andover) with a combined total of more than 850 beds. HHFT's targets during 2014-2015 and 2015-2016 were 37 and 34 reportable hospital-acquired C. difficile cases, respectively. As per local agreements with the CCGs, any breach of those targets resulted in a £10,000 penalty per case unless the CCG appeal panel members deemed the cases unavoidable.
Testing methods and definitions
In HHFT, patients with type 5-7 stools based on the Bristol Stool Chart were identified as having possible CDI and stools were screened by a NAAT test followed by a toxin EIA. Mandatory reporting was based on national guidance as described above (Department of Health, 2012) . The patient's clinical condition was taken into consideration when making management and clinical choices regarding therapy (which is not the focus of this report). Hospital onset cases of C. difficile were defined as those in which stool samples were collected for testing 48 h after admission and were PCR-positive.
On-the-spot RCA by the IPCN and referrals to the MDT-RCA forum
Over the 24-month period, all hospital-onset C. difficilepositive cases identified were initially investigated by the IPCN, antibiotic pharmacist and ward staff (on-the-spot). Realtime feedback was performed on all these cases and learning points were subsequently disseminated in various ways including through mandatory training, governance reports and infection control committee reports to Trust boards.
Cases of toxigenic hospital-onset CDI were reported to Public Health England and went forward to the MDT-RCA forum for review. Some non-toxigenic (non-reportable) cases were also referred to the MDT-RCA forum due to identified shortfalls, lapses of care or possible cross-infection. The findings from the MDT-RCA forum were reported to the Serious Event Review Group (SERG) for Trust-wide evaluation and feedback to divisional governance groups and subsequent actions were agreed.
MDT-RCA forum meetings, cost estimation and referral to CCG panel
MDT-RCA forums were held monthly at each acute hospital site, i.e. two panels per month. Minutes of these meetings were reviewed to calculate the number of staff members who attended and their category and grades. Minimum and maximum hourly pay rates for each staff category/grade (Royal College of Nursing, 2016) were calculated using NHS pay scales based on banding or seniority. The minimum and maximum hourly rates for each individual staff grade/category were multiplied by the number of attendances to get an actual basic cost of staff for the MDT-RCA.
Additionally, deviation costs or opportunity costs were estimated based on cost for time spent preparing paperwork and data gathering for each case prior to the MDT-RCA and physically attending the MDT-RCA followed by writing reports. These tasks were regarded as a deviation from the routine or usual activities for that staff member. The minimum deviation cost was calculated to be equal to the minimum actual cost spent in each MDT-RCA for each staff category, if staff members were not involved in pre-meeting data gathering. The maximum deviation cost was calculated to be equal to the maximum actual cost spent for each MDT-RCA forum and an equal cost for similar time spent on pre-meeting preparations, plus the cost of staff not carrying out their routine revenue-generating procedures/ activities at those times, i.e. double the maximum actual cost. Potential total costs were calculated by adding together actual basic costs and deviation costs.
Each toxigenic C. difficile case was reviewed in the MDT-RCA forum in detail to determine if there was a lapse in patient care and, if not, to prepare a report to the CCG panel for appeal, based on local CCG criteria which are based on national guidance (NHS Improvement, 2017) . The decisions of the CCG panel were reviewed and shared with the Executive and Divisional Boards. Potential savings were calculated for each successful case, meaning avoidance of £10,000 per each successful case.
Results
Over the 24-month period (June 2014 to June 2016), 509 C. difficile cases were detected in the microbiology laboratory in HHFT by NAAT screening, of which 207 (40.6%) were hospital-acquired, all of which had on-the-spot RCA. A total of 69 (33%) of these hospital-acquired cases were reportable to Public Health England (PHE) under current guidelines (Department of Health, 2012). These, together with 15 non-reportable cases (i.e. total 84 cases [40%]), were referred by the IPCN to the MDT-RCA forum. Further details on these cases are included in Table 1 . Sixteen patients were referred to the MDT-RCA forum despite having diarrhoea on admission, as there was a more than 48-h delay in sending stool samples for C. difficile. These were therefore reported as part of the Trust's cases. Only 50% of these patients received antibiotics in the three months before the diagnosis of C. difficile, and in just under 90% of cases these antibiotics were unavoidable as there were clinical and/or microbiological reasons for these.
Key learning themes from the 84 cases are shown in Table 2 . The main issues encountered were the delay in isolating symptomatic patients and the delay in sending stool samples to the laboratory. There were also concerns raised with lack of documentation, such as the clinical and nursing teams not completing the Trust C. difficile care pathway, and Diarrhoea and Vomiting risk assessment. All the key learning outcomes covered in Table 2 were issues raised by the IPCN while doing on-the-spot RCA, generating immediate feedback for the wards and staff involved. No additional learning points were picked up in the MDT-RCA.
Actual, deviation and potential total costs of these MDT-RCA forum meetings are provided in Table 3 . The estimated minimum and maximum actual basic cost of the staff attending the MDT-RCA meetings over the 24-month period were £11,897.87 and £17,216.67. Deviation costs were estimated to be in the range of £11,897.87-£34,433.43. When added together the total estimated costs for staff attending the meetings were in the range of £23,795.74-£51,670.10. These calculations did not include additional expenses such as the cost of meeting rooms and other overheads.
Among the 84 cases reviewed in the MDT-RCA forum during this period, 27 were submitted to the CCG to demonstrate no lapse of care and to appeal against any financial penalties in the event of target breaches. Out of these 27 cases, the CCG appeal panel upheld 14 cases, as there was no lapse of care identified. In 13 cases, the CCG disagreed with the Trust's MDT-RCA findings that there were no lapses of care (Table 4) .
The potential savings from 14 successful appeal cases would have been the avoidance of £140,000 in sanctions/ fines; however, during the 24-month period, we only had two breached cases, i.e. our sanctions or fines by the CCG for that period would have been equal to only £20,000. Deducting this from the potential costs of the MDT-RCA, we conclude that during the period evaluated, the Trust potentially lost £3795.74-£31,670.10. These calculations do not include additional costs incurred during preparation by the DIPC, deputy DIPC and the governance team in submitting these cases, the cost of travel and attending or dialling in to four half-day meetings to present to the CCG panel.
The number of CDI cases over the 24-month period was also looked at to see if there was any reduction. In the first quarter of the MDT-RCA (i.e. June to August 2014), there was a total of 11 reportable hospital-acquired CDIs and there were nine cases in the final quarter (i.e. March to May 2016). However, the number of reportable CDIs were on a downwards trend before the introduction of the MDT-RCA. Figure 1 showing the number of reportable CDI per 1000 bed-days.
Discussion
To our knowledge, this is the only published report discussing the costs of C. difficile MDT-RCA to NHS Hospital Trusts in light of appeals against sanctions from the CCG.
No additional learning points were identified during the MDT-RCA meetings above those covered in Table 2 . It is possible this may reflect organisational issues with the methodology of the process and delivery of actions and outcomes from these, as opposed to the conceptual approach. For instance, we found that some issues or learning points were recurrent (documentation, processing issues, speed of isolation of suspected cases) suggesting challenging barriers to effectively overcome, some perhaps due to constraints in resource or estate. Although no additional learning points were identified, one possible benefit of the MDT-RCA meetings may have been heightening the awareness of CDI among staff that attended.
The main aims of the MDT-RCAs are to improve quality of care; however, we focused on exploring the costs of these to the Trust. Although there are some data on the cost of managing hospital outbreaks, gathering precise data on the cost of HCAI is challenging, and attempts to count the cost of HCAI need to account for both actual expenditure and opportunity costs (Bou et al., 2009; Dik et al., 2016; Garlantezec et al., 2011; Jiang et al., 2016; Otter et al., 2016; Perencevich et al., 2007; Spearing et al., 2000; Stone et al., 2003) . To our knowledge, there are no published data on the cost of MDT-RCA meetings in HCAI including C. difficile. Based on our calculations, the cost of the MDT-RCA forums over the two-year period in HHFT potentially cost £23,795.74-£51,670.10 and our potential saving for Results are presented as n (%). *This includes antibiotics started in primary care. Among this cohort, in the three-month period before the CDI diagnosis, 24% had a single antibiotic course, 23% had two antibiotic courses and 53% of cases had at least three courses of antibiotics. Interestingly, based on the MDT-RCA findings, prescriptions were unavoidable in 89%, avoidable in 3.5% (choice or requirements) and indeterminable due to lack of information or documentation in 7.5%. † Not initiated for clinical reasons, e.g. patient was on priorities of care pathway. ‡ Difficult to decide based on information from notes if these cases were avoidable; as a result they were not submitted for appeal.
the two breached cases was only £20,000 meaning that during that period the Trust potentially lost £3795.74-£31,670.10. Therefore, for this cohort the MDT-RCA did not seem to be cost-effective. We need to emphasise that our calculation does not take into account the cost of patient care, bed loss, additional cleaning and waste disposal, impact on patient outcomes, antibiotic stewardship and additional staff training. In addition, 27 cases were forwarded to the CCG for appeal against sanctions during this time period and the cost to the Trust of preparing for the appeal and the deviation costs of the DIPC, deputy DIPC and governance team in submitting these cases and participating in the CCG panel meetings has not been included. Furthermore, the cost of the CCG panel, which can be significant to the NHS and the taxpayer, has not been calculated within this report. Another interesting point, in our view, regarding the appeal process is that although there are national criteria to define what may constitute 'lapse of care' (NHS Improvement, 2017), appeal panels need to accept that the burden of proof needs to be greater and that a lapse in care needs to have a degree of causality. For example, a lapse would result from in-hospital transmission proven by ribotyping or a major issue in antimicrobial prescribing/ stewardship. Where there were suboptimal practices relating to delays in isolation or obtaining and testing a stool sample or a deficiency in antimicrobial documentation (assuming choice, duration and indication were correct) these should be termed 'deviations from best practice' and should not be subject to financial penalties or lapse of care.
Although the total number of reportable CDIs did reduce slightly from the first quarter to the last quarter observed (i.e. from June-August 2014 to March-May 2016) from 11 to nine, respectively, the numbers overall were on a downwards trend before this (Figure 1 ). For this reason, it is difficult to say that the MDT-RCA had a positive impact on reducing the number of CDI cases.
One of the reasons for CCG panel appeal failures included the concomitant (or possibly incidental) finding with Norovirus infection. As explained in Table 4 , the CCG panel felt that as the Norovirus was acquired during the patients' hospital stay, it meant that there was a breach in infection prevention practices and hence even an incidental finding of C. difficile was regarded as a lapse of patient care. We believe the MDT-RCA has no impact on occurrence of Norovirus and subsequent concomitant or incidental reportable or non-reportable C. difficile detection. The Infection Control Committee and the Trust board agreed that regardless of targets or sanctions, the trust will continue to test for C. difficile during Norovirus outbreaks, as identification and isolation of colonised cases should prevent onward transmission and hospital outbreaks.
Different CCGs may have different regulations or terms of reference for what may constitute a "lapse of care" and a *Costs are based on 1-h meeting time that includes real time spent on each case (30-45 min) plus travel time to and from meeting venues. These are only basic costs and do not include supplements for on-call, awards or additional lead roles. This does not include staff time spent in sending statements or letters when they were physically unable to attend the meetings including consultants for 34 RCAs, antimicrobial pharmacists for 22 RCAs, governance and facilities for 54 RCAs. They do not include the cost of meeting rooms and other overheads.
-Basic cost of staff / h = minimum / maximum hourly rate for one staff category or grade.
-Actual basic cost = basic cost of staff group × number of staff in that category or grade attended these meetings.
-Minimum deviation cost = minimum actual cost spent in each MDT-RCA for each staff category or grade if staff members were not involved in pre-meeting data gathering. -Maximum deviation cost = maximum actual cost spent for each MDT-RCA forum plus an equal cost for similar time spent on pre-meeting preparations, plus the cost of staff not carrying out their routine revenue-generating procedures / activities at those times, i.e. double the maximum actual cost. -Potential total costs = actual basic costs plus deviation costs.
† In HHFT, the microbiologist is also the DIPC (the additional payment supplement has not been included). This highlights the challenges associated with laboratory mergers and the impact this have on turnaround times of results. We continue to improve our transport between our sites
Deviation from hospital antibiotic guidelines, although the antibiotic was appropriate there was no documentation why the deviation from the usual trust guidelines occurred
As in the on-the-spot RCA improvement, documentation is required; however, this should not be regarded as lapse of care but may be a deviation of care
Delay in commencing C. difficile treatment or care pathway without documentation as to why this had occurred
As above
Failure to narrow down antibiotics based on culture and sensitivity without documentation why this happened As above *One or more of these could be applicable to each case. weakness of this work is that it is not able to ascertain what is happening nationally. Additionally, the impact of an MDT-RCA approach in other organisations may be different from our experience; immeasurable benefits on quality of care may well exist and it may provide opportunities for relationship-building and team-working between different specialties. It is, however, our view that it is no more effective than a more responsive, real-time and leaner on-thespot investigation approach encompassing timely feedback and enhanced individualised education. Ultimately, on a theoretical level, further reductions beyond a certain baseline may be realistically difficult to achieve for an organisation, given the clinical context of current practice and epidemiology of C. difficile. In conclusion, we found that MDT-RCA can be very costly without additional benefit to the on-the-spot investigation by IPCNs on C. difficile numbers or patients' outcome. Additionally, participation in the CCG appeal process can add further costs to Trusts and the NHS. Trusts should invest in smarter mechanisms to tackle HCAIs, including on-the-spot direct feedback, education to clinical/nursing staff and targeted long-term improvements to sustain lower numbers of CDIs and improve patient outcomes.
